Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Mapping antibody escape in SARS-CoV-2: Several antibodies are in use or under development as therapies to treat COVID-19. As new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge, it is important to predict whether they will remain susceptible to antibody treatment. Starr et al. used a yeast library that covers all mutations to the SARS-CoV-2 receptor-binding domain that do not strongly disrupt binding to the host receptor (ACE2) and mapped how these mutations affect binding to three leading anti–SARS-CoV-2 antibodies. The maps identify mutations that escape antibody binding, including a single mutation that escapes both antibodies in the Regeneron antibody cocktail. Many of the mutations that escape single antibodies are circulating in the human population. Science , this issue p. 850
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Escape maps are consistent with viral mutations selected in cell culture and a persistently infected patient. (A) Viral escape mutations selected by Regeneron with spike-pseudotyped VSV in cell culture in the presence of antibody (12). (B) Escape maps like those in Fig. 1A, but showing only mutations accessible by single-nucleotide changes to the Wuhan-Hu-1 sequence, with nongray colors indicating mutations in cell culture (red), the infected patient (blue), or both (purple). Figure S5 shows these maps colored by how mutations affect ACE2 affinity or RBD expression. (C) Dynamics of RBD mutations in a patient treated with REGN-COV2 at day 145 of infection (black dot-dash vertical line). E484A rose in frequency in linkage with F486I, but because E484A is not an escape mutation in our maps, it is not shown in other panels. See also fig. S4. (D) The escape mutations that arise in cell culture and the infected patient are single-nucleotide–accessible and escape antibody binding without imposing a large cost on ACE2 affinity [as measured using yeast display (7)]. Each point is a mutation, with shape and color indicating whether it is accessible and selected during viral growth. Points farther to the right on the x axis indicate stronger escape from antibody binding; points higher up on the y axis indicate higher ACE2 affinity.](https://figures.cochat.ai/paper-figures/91cf075ab18741e0a80bfb01ad2b708a/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-2.jpg)

![Fig. 4 Structural context of escape mutations. (A) Escape maps projected on antibody-bound RBD structures. [REGN10933 and REGN10987: Protein Data Bank (PDB) ID 6XDG (11); LY-CoV016: PDB ID 7C01 (13)]. Antibody heavy- and light-chain variable domains are shown as blue cartoons, and the RBD surface is colored to indicate how strongly mutations at that site mediate escape (white indicates no escape, red indicates strongest escape site for that antibody or cocktail). Sites where no mutations are functionally tolerated are colored gray. (B) For each antibody, sites were classified as direct antibody contacts (non-hydrogen atoms within 4 Å of antibody), antibody-proximal (4 to 8 Å), or antibody-distal (>8 Å). Each point indicates a site, classified as escape (red) or non-escape (black). The dashed gray line indicates the cutoff used to classify sites as escape or non-escape (see materials and methods for details). Red and black numbers indicate how many sites in each category are escape or non-escape sites, respectively. Interactive visualizations are at https://jbloomlab.github.io/SARS-CoV-2-RBD_MAP_clinical_Abs/, and hypothesized mechanisms of escape and additional structural details for labeled points are shown in fig. S6.](https://figures.cochat.ai/paper-figures/854cbba408614d74b93381682c26dd9e/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several of the RBD mutations directly affect angiotensin-converting enzyme 2 (ACE2) receptor-binding affinity, which may affect infectivity, viral load, or transmissibility.11, 12, 13, 14”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations found in emergent S variants decrease sensitivity to neutralization by mAbs, convalescent plasma, and sera from vaccinated individuals (27, 37, 58, 61–70).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The B.1.1.7, B.1.351, and P.1 lineages all harbor a N501Y mutation in the RBD, which increases the affinity for the ACE2 receptor (57, 58), and a D614G mutation, which increases virion spike density, infectivity, and transmissibility (59, 60).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We tested four clinically approved monoclonal antibodies that target the RBD 18,19 (bamlanivimab (LY-CoV555), etesevimab (LY-CoV016), casirivimab (REGN10933) and imdevimab (REGN10987))”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
fastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM
Li, H. (2013) · DROPS (Schloss Dagstuhl – Leibniz Center for Informatics) · doi:10.48550/arxiv.1303.3997 · Cited by 5,159
Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEM
Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 4,932
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Snakemake—a scalable bioinformatics workflow engine
Köster, J., & Rahmann, S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts480 · Cited by 2,780
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Research works printed but not linked: 2
- 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
- Regeneron Pharmaceuticals Inc. “Regeneron’s casirivimab and imdevimab antibody cocktail for COVID-19 is first combination therapy to receive FDA emergency use authorization ” press release (21 November 2020); https://investor.regeneron.com/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive/.
Cited by
Items 501–600 of 750
Constrained evolutionary funnels shape viral immune escape
Huot, M., Wang, D., Shakhnovich, E. I., Monasson, R., & Cocco, S. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536956123 · Cited by 10
Chaturvedi, P., Kelich, P., Nitka, T. A., & Vuković, L. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c07436 · Cited by 7
Ueno, M., Iwata‐Yoshikawa, N., Matsunaga, A., Okamura, T., Saito, S., Ashida, S., Yoshida, I., Nagashima, M., Asakura, H., Yaoita, Y., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105297 · Cited by 7
Williams, A. H., & Zhan, C. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c02123 · Cited by 8
Kuhaudomlarp, S., & Imberty, A. (2022) · IUBMB Life · doi:10.1002/iub.2692 · Cited by 7
Cianfarini, C. L., Hassler, L., Wysocki, J. A., Hassan, A., Nicolaescu, V. I., Elli, D., Gula, H., Ibrahim, A. M., Randall, G. C., Henkin, J., et al. (2024) · Cells · doi:10.3390/cells13030203 · Cited by 8
Zhang, Y., Jiang, N., Qi, W., Li, T., Zhang, Y., Zhang, H., Wu, J., Zhu, Z., Ai, J., Qiu, C., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.01.016 · Cited by 7
Frei, L., Gao, B., Han, J., Taft, J. M., Irvine, E. B., Weber, C. R., Kumar, R. K., Eisinger, B. N., & Reddy, S. T. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.09.561492 · Cited by 7
Exposing structural variations in SARS-CoV-2 evolution
Yang, J., Zhang, P., Cheng, W. X., Lu, Y., Wu, G., & Ren, G. (2021) · Scientific Reports · doi:10.1038/s41598-021-01650-3 · Cited by 6
“Also, bioassay experiments showed that the K417N mutation certainly conferred > 100-fold reduced susceptibility to antibody etesevimab 39 and about tenfold reduced susceptibility to antibody casirivimab 40 .”
BackgroundTang, H., Ke, Y., Liao, Y., Bian, Y., Yuan, Y., Wang, Z., Li, Y., Ma, H., Sun, T., Zhang, B., et al. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.11.005 · Cited by 7
“Previous mutational screening demonstrated REGN-10987 is susceptible to mutations in residues N440/K444/V445/G446/P499 (Baum et al., 2020; Starr et al., 2021) (Fig.”
Divergent pathogenetic outcomes in BALB/c mice following Omicron subvariant infection
Powers, J. M., Leist, S. R., Mallory, M. L., Yount, B. L., Gully, K. L., Zweigart, M. R., Bailey, A. B., Sheahan, T. P., Harkema, J. R., & Baric, R. S. (2024) · Virus Research · doi:10.1016/j.virusres.2024.199319 · Cited by 8
“…also enable escape from pre-existing neutralizing antibodies due to changes at key antigenic epitopes, supporting the hypothesis that new serotypes are emerging that are antigenically distinct from the original Wuhan ancestral strain (Tsai et al., 2021; Greaney et al., 2021; Starr et al., 2021).”
BackgroundMajoumo‐Mbe, F., Nono, J. H., Sangbong, N. A., & Efeti, I. I. (2024) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2024.123184 · Cited by 6
Thalén, N., Karlander, M., Lundqvist, M., Persson, H., Hofström, C., Turunen, S. P., Godzwon, M., Volk, A.-L., Malm, M., Ohlin, M., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06508-8 · Cited by 7
“…7,16 – 19 and, both yeast and bacterial cell surface display have been used for epitope determination 18,20,21 Recently, modernized methods such as yeast mating enabledhigh-throughputscreeningofantibodiestargetingSARS-CoV-2 22,23 and yeast display have been used to map escape mutants on RBD 24,25 .”
Lyukmanova, E. N., Pichkur, E., Nolde, D. E., Kocharovskaya, M. V., Manuvera, V. A., Shirokov, D. A., Kharlampieva, D. D., Grafskaia, E. N., Svetlova, J. I., Лазарев, В. Н., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-07422-9 · Cited by 6
“Consistent with our Δ G calculations, other RBD mutations described for the SARS-CoV-2 variants that lie outside the REGN10987 binding interface do not affect the antibody ’ s af fi nity in the most cases 8,34,62 (Fig.”
InfluentialEngineered DPP4 decoy confers broad-spectrum inhibition of MERS-CoV infection
Nishioka, K., Sakai, Y., Motooka, D., Iwata‐Yoshikawa, N., Tojo, H., Matoba, S., Nagata, N., Nakaya, T., Arimori, T., & Hoshino, A. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100018 · Cited by 6
Cheng, Y., Zheng, D., Zhang, D., Guo, D., Wang, Y., Liu, W. Y., Liang, L., Hu, J., Shi, H., & Luo, T. (2023) · Journal of Molecular Modeling · doi:10.1007/s00894-023-05509-4 · Cited by 6
Multiplexed on-yeast serological assay for immune escape screening of SARS-CoV-2 variants
López-Morales, J., Vanella, R., Utzinger, T., Schittny, V., Hirsiger, J. R., Osthoff, M. F., Berger, C. T., Guri, Y., & Nash, M. A. (2023) · iScience · doi:10.1016/j.isci.2023.106648 · Cited by 8
Gerashchenko, G. V., Hryshchenko, N. V., Melnichuk, N., Marchyshak, T., Chernushyn, S. Y., Demchyshina, I. V., Chernenko, L. M., Kuzin, I., Tkachuk, Z. Y., Kashuba, V. I., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25618 · Cited by 7
Korosec, C. S., Wahl, L. M., & Heffernan, J. M. (2024) · Virus Evolution · doi:10.1093/ve/veae006 · Cited by 9
2020 Hindsight: Should evolutionary virologists have expected the unexpected during a pandemic?
Goldhill, D. H., & Barclay, W. (2021) · Evolution · doi:10.1111/evo.14317 · Cited by 5
Neuman, B. W., Brashear, W. A., Brun, M., Chaki, S. P., Fischer, R. S. B., Guidry, S. J., Hill, J. E., Hillhouse, A., Johnson, C. D., Kahl-McDonagh, M. M., et al. (2021) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.21-0542 · Cited by 6
Zoonotic and anthropozoonotic potential of COVID-19 and its implications for public health
El-Sayed, A., Abdel‐Daim, M. M., & Kamel, M. S. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16415-8 · Cited by 6
Walter, K. S., Kim, E., Verma, R., Altamirano, J., Leary, S., Carrington, Y. J., Jagannathan, P., Singh, U., Holubar, M. K., Subramanian, A. K., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad001 · Cited by 8
Exploring epitope and functional diversity of anti-SARS-CoV2 antibodies using AI-based methodsPreprint
Dumet, C., Jullian, Y., Musnier, A., Rivière, P., Poirier, N., Watier, H., Bourquard, T., & Poupon, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.23.424199 · Cited by 5
Bier, C., Edelmann, A., Theil, K., Schwarzer, R., Deichner, M., Gessner, A., Hiergeist, A., Rentschler, U., Gohl, P., Kuchta, A. L., et al. (2021) · medRxiv · doi:10.1101/2021.05.05.21254713 · Cited by 6
Liu, H., Kaku, C. I., Song, G., Yuan, M., Andrabi, R., Burton, D. R., Walker, L. M., & Wilson, I. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.15.472864 · Cited by 6
Predicting Immune Escape with Pretrained Protein Language Model EmbeddingsPreprint
Swanson, K., Chang, H. Y., & Zou, J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.30.518466 · Cited by 7
Cohen, A. A., Keeffe, J. R., Rorick, A. V., Rho, S., Fils, A.-C. I. P., Manasyan, L., Gao, H., Gnanapragasam, P. N. P., Funke, H. H., Randolph, T. W., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113649 · Cited by 7
Rahman, M. A., Becerra‐Flores, M., Patskovsky, Y., de Castro, I. S., Bissa, M., Basu, S., Shen, X., Williams, L. D., Sarkis, S., N’Guessan, K. F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1139402 · Cited by 5
Zhang, X. Z., Wu, J., Luo, Y., Wang, Y., Wu, Y., Xu, X., Zhang, Y., Kong, R., G, Y., Sun, Y., et al. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae183 · Cited by 6
“…as spike mutations that met one or more of the following criteria: (1) having a median ≥ 5-fold reduction in susceptibility to a clinical stage mAb compared with WT according to CoV-RDB [34] and/or (2) having > 0.1 average antibody escape from aggregated deep mutational scanning (DMS) data [53].”
MethodInfluentialHigh-throughput specificity profiling of antibody libraries using ribosome display and microfluidics
Wagner, E. K., Carter, K. P., Lim, Y. W., Chau, G. J., Enstrom, A., Wayham, N. P., Hanners, J.-M., Yeh, C.-L. C., Fouet, M., Leong, J., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100934 · Cited by 7
Verkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031646 · Cited by 6
Sandhya, K. S., & Nair, A. S. (2023) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-023-00492-y · Cited by 4
Haque, S., Mathkor, D. M., Alkhanani, M., Bantun, F., Momenah, A. M., Faidah, H. S., Jalal, N. A., & Kumar, V. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2194007 · Cited by 6
“Accordingly, RBD mutations that can improve binding affinity with ACE2 and/or affect antibody neutralization have been extensively mapped through high-throughput mutational studies (C. Chen et al., 2021; J. Chen et al., 2020; Greaney et al., 2021; Starr et al., 2021).”
BackgroundKetaren, N. E., Mast, F. D., Fridy, P. C., Olivier, J. P., Sanyal, T., Sali, A., Chait, B. T., Rout, M. P., & Aitchison, J. D. (2024) · eLife · doi:10.7554/elife.89423.3 · Cited by 5
Fattahi, A., Afaghi, P., & Ghandi, K. (2021) · Catalysts · doi:10.3390/catal11020191 · Cited by 5
Nevermann, N., Wiering, L., Wu, H., Moroder, P., Brandl, A., Globke, B., Krenzien, F., Raschzok, N., Schöning, W., Lurje, G., et al. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13696 · Cited by 5
Searching for escape-resistant anti–SARS-CoV-2 neutralizing antibodies
Mahla, R. S., & Dustin, L. B. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157416 · Cited by 5
Tuccori, M., Convertino, I., Ferraro, S., Cappello, E., Valdiserra, G., Luca, G. D., Franchini, M., & Focosi, D. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2058486 · Cited by 4
“In vitro, imdevimab is resistant to Spike mutations E406W (>100 folds reduction in neutralization compared to wild-type strain), N439K (25–100 folds), N440K (28–96 folds), K444L/M/N/Q/T (>100 folds), V445A (>100 folds), G446V (>100 folds), N450D (9–32 folds), Q498H (17 folds), P499S (>100 folds), E484K (16 folds); whi…”
Zhou, W., Xu, C., Luo, M., Wang, P., Xu, Z., Xue, G., Jin, X., Huang, Y., Li, Y., Nie, H., et al. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105509 · Cited by 5
“In addition, there are still many mutations (including K417 N, Y453F, A475V, L452R, V483A, F490L et al.) that are reported to show resistance to some neutralizing antibodies [40,45].”
Multi-task learning for predicting SARS-CoV-2 antibody escape
Gross, B., & Sharan, R. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.886649 · Cited by 5
“As a fi rst test, we calculate viral escape of single amino-acid substitution from new, yet unseen antibodies: LY-CoV016, REGN10987 and REGN10933 Starr et al. (2021b).”
BackgroundMethodInfluentialTang, H., Ke, Y., Wang, L., Wu, M., Sun, T., & Zhu, J. (2022) · Pharmaceuticals · doi:10.3390/ph15081002 · Cited by 4
Sun, C., Chi, H., Yuan, F., Li, J., Yang, J., Zheng, A., Wang, F., Sun, L., Zhang, Y., Hu, P. F., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2166-y · Cited by 5
Self-citationMalisheni, M. M., Bates, M., Rizvanov, A. A., & MacAry, P. A. (2022) · Pathogens · doi:10.3390/pathogens11121437 · Cited by 5
Fredericks, A. M., East, K. W., Shi, Y., Liu, J., Maschietto, F., Ayala, A., Cioffi, W. G., Cohen, M., Fairbrother, W. G., Lefort, C. T., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1080964 · Cited by 5
Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
Zekri, L., Ruétalo, N., Christie, M., Walker, C., Manz, T., Rammensee, H., Salih, H. R., Schindler, M., & Jung, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1112505 · Cited by 6
Tayyar, R., Wong, L. K., Dahlen, A., Shu, E., Pandey, S., & Liu, A. Y. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14055 · Cited by 5
Adaptation of SARS-CoV-2 to ACE2 H353K mice reveals new spike residues that drive mouse infection
Li, K., Verma, A., Li, P., Ortiz, M. E., Hawkins, G. M., Schnicker, N., Szachowicz, P. J., Pezzulo, A. A., Wohlford-Lenane, C., Kicmal, T., et al. (2024) · Journal of Virology · doi:10.1128/jvi.01510-23 · Cited by 10
“The K417E mutation and other changes at residue 417 have been associated with evasion of the antibody response, including loss of recogni tion by several monoclonal antibodies that are used therapeutically, such as REGN10933 (marketed as casirivimab) (52–54).”
BackgroundA Highly Potent Antibody Effective Against SARS-CoV-2 Variants of ConcernPreprint
Fenwick, C. W., Turelli, P., Perez, L. H., Pellaton, C., Esteves-Leuenberger, L., Farina, A., Campos, J., Lana, E., Fiscalini, F., Raclot, C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3844718 · Cited by 5
The Functional Landscape of SARS-CoV-2 3CL ProteasePreprint
Iketani, S., Hong, S. J., Sheng, J., Bahari, F., Culbertson, B., Atanaki, F. F., Aditham, A. K., Kratz, A. F., Luck, M. I., Tian, R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.23.497404 · Cited by 5
Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2Preprint
Ragonnet‐Cronin, M., Nutalai, R., Huo, J., Dijokaite-Guraliuc, A., Das, R., Tuekprakhon, A., Supasa, P., Liu, C., Selvaraj, M., Groves, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.14.500063 · Cited by 5
Mouse-adapted SARS-CoV-2 Omicron BA.5 infection induces post-acute lung fibrosis in BALB/c mice
Powers, J. M., Leist, S. R., Suryadevara, N., Zost, S. J., Binshtein, E., Abdelgadir, A., Mallory, M. L., Edwards, C. E., Gully, K. L., Hubbard, M. L., et al. (2025) · Journal of Virology · doi:10.1128/jvi.01406-25 · Cited by 8
INSIGHT OF PANDEMIC COVID-19: DEVELOPMENTS AND CHALLENGES
Muneer, M. A., Arshad, M., Abbas, G., Arshad, M., Munir, K., Iqbal, A., Mustafa, A., Amin, Q., Khan, M. A., Qureshi, R. A., et al. (2023) · Pakistan Journal of Science · doi:10.57041/pjs.v75i1.831 · Cited by 4
Gallinaro, A., Falce, C., Pirillo, M. F., Borghi, M., Grasso, F., Canitano, A., Cecchetti, S., Baratella, M., Michelini, Z., Mariotti, S., et al. (2025) · Vaccines · doi:10.3390/vaccines13030216 · Cited by 5
Suarez, R., Gregory, D. A., Baker, D. A., Rushford, C., Hunter, T., Minor, N. R., Russ, C. M., Copen, E. E., O’Connor, D. H., & Johnson, M. C. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1012850 · Cited by 4
“%) and Q493K (56%), which have been shown to affect antibody escape [17,18] and may also have small effects on ACE2 binding, with effects ranging from slightly increasing to modestly decreasing binding depending on the genetic background [19].”
Structural Insights into the SARS-CoV-2 Spike Protein and Its Implications for Antibody Resistance
Yamamoto, Y., & Noguchi, K. (2025) · Biomolecules · doi:10.3390/biom15111489 · Cited by 5
“Structural analyses have shown that the N501Y substitution enhances ACE2 binding by introducing two new hydrogen bonds between Y501 and ACE2 residues D38 and K353, and by establishing a strong π – π stacking interaction between the aromatic ring of Y501 and Y41 of ACE2 [61,86].”
Hassan, S., West, K. A., Conry-Cantilena, K., & Giorgi, V. D. (2021) · Transfusion · doi:10.1111/trf.16751 · Cited by 4
Sorokina, M., Belapure, J., Tüting, C., Paschke, R., Papasotiriou, I., Rodrigues, J., & Kastritis, P. L. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167637 · Cited by 4
“Both Y453F and N439K may potentially be escape substitutions.(59) (d) N501Y.”
Kumar, S., Kumari, K., & Azad, G. K. (2022) · Moscow University Biological Sciences Bulletin · doi:10.3103/s0096392522040125 · Cited by 4
Pham, V. H., Pham, H. T., Balzanelli, M. G., Distratis, P., Lazzaro, R., Nguyễn, Q. V., Tran, V. Q., Tran, D. K., Phan, L. D., Pham, S. M., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13081364 · Cited by 5
An In Silico Design of Peptides Targeting the S1/S2 Cleavage Site of the SARS-CoV-2 Spike Protein
Ho, C. M., Nazarie, W. F. W. M., & Lee, C. (2023) · Viruses · doi:10.3390/v15091930 · Cited by 4
“The mutated variants have developed resistance towards monoclonal antibodies, such as REGEN-COV, bamlanivimab, etesevimab, bebtelovimab, and sotrovimab, resulting in ineffective treatment [11,14–17].”
BackgroundContinued selection on cryptic SARS-CoV-2 observed in Missouri wastewater
Gregory, D. A., Rushford, C., Hunter, T., Lin, C.-H., Darby, C. W., Niehues, N. D., Semkiw, E., Reynolds, M., Wenzel, J., & Johnson, M. C. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011688 · Cited by 4
Ruotolo, L., Silenzi, S., Mola, B., Ortalli, M., Lazzarotto, T., & Rossini, G. (2024) · Virology Journal · doi:10.1186/s12985-024-02483-y · Cited by 6
Chang, K. P., Reynolds, J. M., Liu, Y., & He, J. J. (2022) · Vaccines · doi:10.3390/vaccines10020248 · Cited by 5
Contreras, M., Vicente, J., Cerón, J. M. C., Martínez-Subiela, S., Urra, J. M., Rodríguez‐del‐Río, F. J., Ferreras‐Colino, E., Vaz‐Rodrigues, R., de Mera, I. G. F., Antunes, S., et al. (2023) · European Journal of Immunology · doi:10.1002/eji.202250206 · Cited by 5
Khosravi, D., Soloff, H., Langsjoen, R. M., Bombin, A., Kelley, C. F., Ray, S. M., Gunthel, C. J., Zanoni, B. C., Nguyen, P.-V., Waggoner, J. J., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad054 · Cited by 5
Perception of Remote Learning by Fixed Prosthodontic Students at a Romanian Faculty of Dentistry
Ţănculescu, O., Apostu, A., Doloca, A., Solomon, S. M., Diaconu-Popa, D. A., Ciongradi, C. I., Vieriu, R.-M., Aungurencei, O. D., Fătu, A. M., Ioanid, N., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043622 · Cited by 4
The in vitro and in vivo potency of CT-P59 against Delta and its associated variants of SARS-CoV-2Preprint
Ryu, D.-K., Woo, H., Kang, B., Noh, H., Kim, J., Seo, J.-M., Kim, C.-M., Kim, M., Kim, J., Kim, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.23.453472 · Cited by 8
Cheng, M. H., Krieger, J., Xiang, Y., Kaynak, B., Shi, Y., Arditi, M., & Bahar, İ. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3907841 · Cited by 4
Pelzek, A. J., Ebtehaj, S., Lulo, J. E., Zhang, L., Balduf, O., Dolan, L., Zhang, C., Wan, S., An, G., Kankam, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.06.479332 · Cited by 4
Balech, B., Presti, A. L., Telegrafo, C., Maisto, L., Giombini, E., Martino, A. D., Ambrosio, L., Tullo, A., & Stefanelli, P. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333093 · Cited by 4
mRNA delivery of mosaic-8 pan-sarbecovirus RBD vaccines elicits distinct antibody epitope signatures
Cohen, A. A., Keeffe, J. R., Manasyan, L., Madireddy, I., Fils, A.-C. I. P., Dam, K.-M. A., Stober, H. E., Hills, R. A., Moon, W. J., Lin, P. J. C., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117335 · Cited by 6
“36-41 We classified RBD residues by epitopes defined by structural properties and conservation/variability across sarbecoviruses: class 1 and class 2 RBD epitopes exhibit higher, and class 4, class 1/4, and portions of class 3 and class 5 epitopes exhibit lower sequence variability across…”
Evaluating SARS-CoV-2 antibody resilience via prediction and design of escape viral variants
Huot, M., Rosenbaum, P., Planchais, C., Mouquet, H., Monasson, R., & Cocco, S. (2026) · Cell Systems · doi:10.1016/j.cels.2026.101673 · Cited by 6
Casirivimab - Imdevimab in Covid 19 – Early Indian experience
Venkitakrishnan, R., Augustine, J., Ramachandran, D., & Cleetus, M. (2021) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2021.09.014 · Cited by 3
Discovery of Highly Potent Small Molecule Pan-Coronavirus Fusion Inhibitors
Curreli, F., Chau, K., Tran, T.-T., Nicolau, I., Ahmed, S., Das, P., Hillyer, C. D., Premenko-Lanier, M., & Debnath, A. K. (2023) · Viruses · doi:10.3390/v15041001 · Cited by 3
Dynamic expedition of leading mutations in SARS-CoV-2 spike glycoproteins
Hasan, M., He, Z., Jia, M., Leung, A. C. F., Natarajan, K., Xu, W., Yap, S., Zhou, F., Chen, S., Su, H., et al. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.05.037 · Cited by 3
“1), mutations have been shown to influence neutralization by both mAbs and antibodies present in polyclonal serum [77,78,83].”
Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2
Guttieres, D., Sinskey, A. J., & Springs, S. L. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab006 · Cited by 3
A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions
Springstein, B. L., Deighan, P., Grabe, G. J., & Hochschild, A. (2021) · mBio · doi:10.1128/mbio.02936-21 · Cited by 4
SPEAR: Systematic ProtEin AnnotatoR
Crown, M. R., Teruel, N., Najmanovich, R., & Bashton, M. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac391 · Cited by 3
Chan, C. E.-Z., Ng, C.-G., Lim, A. P.-C., Seah, S. G. K., Chye, D. H., Wong, S. K. K., Lim, J.-H., Lim, V. Z.-Y., Lai, S.-K., Wong, P.-S., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00455-22 · Cited by 2
Chen, C., Saville, J. W., Martí, M. M., Schäfer, A., Cheng, M. H., Mannar, D., Zhu, X. Q., Berezuk, A., Banerjee, A., Sobolewski, M. D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104798 · Cited by 3
Collaborative effects of 2019-nCoV-Spike mutants on viral infectivity
Fang, S., Lei, C., Li, M., Ming, Y., Liu, L., Zhou, X., & Li, M. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.10.030 · Cited by 3
“A plethora of evidence demonstrates that new variants, particularly those with multiple mutations emerge rapidly, marking a new era in the COVID-19 epidemic [14].”
BackgroundSandhya, K. S., Kishore, A. A., Unni, A., Sunitha, P., V, Sajithra, C. V., & Nair, A. S. (2024) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2024.108719 · Cited by 3
Impact of Missense Mutations on Spike Protein Stability and Binding Affinity in the Omicron Variant
Mahase, V., Sobitan, A., Yao, Q., Shi, X. M., Qin, H. H., Kidane, D., Tang, Q., & Teng, S. (2024) · Viruses · doi:10.3390/v16071150 · Cited by 4
“Notably, the Omicron variant surpasses previous variants with the highest number of mutations in the RBM, such as A484E and R493Q, associated with immune evasion by reducing bindings to host antibodies [10].”
BackgroundIslam, S., Chauhan, V. M., & Pantazes, R. J. (2024) · mAbs · doi:10.1080/19420862.2024.2440586 · Cited by 4
The Yin and Yang of SARS-CoV-2 Mutation and Evolution
Badley, A. D. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.01.023 · Cited by 3
Park, S. H., Kim, H., Kang, H., Kim, J. H., Lee, J., Lim, J., Lee, S., & Jeong, J. (2021) · Annals of Laboratory Medicine · doi:10.3343/alm.2022.42.3.363 · Cited by 3
Sequence similarity of SARS-CoV-2 and humans: Implications for SARS-CoV-2 detection
Li, H., Hong, X., Ding, L., Meng, S., Liao, R., Jiang, Z., & Liu, D. J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.946359 · Cited by 6
Carro, B. (2021) · All Life · doi:10.1080/26895293.2021.1977186 · Cited by 3
A Pre-Vaccination Baseline of SARS-CoV-2 Genetic Surveillance and Diversity in the United States
Capoferri, A. A., Shao, W., Spindler, J., Coffin, J. M., Rausch, J. W., & Kearney, M. F. (2022) · Viruses · doi:10.3390/v14010104 · Cited by 3
PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding
Vanderlinden, E., Boonen, A., Noppen, S., Schoofs, G., Imbrechts, M., Geukens, N., Snoeck, R., Stevaert, A., Naesens, L. M. J., Andreï, G., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105700 · Cited by 5
Ultrafast topological data analysis reveals pandemic-scale dynamics of convergent evolutionPreprint
Bleher, M., Hahn, L., Neumann, M., Ardern, Z., Patiño-Galindo, J. Á., Carrière, M., Bauer, U., Rabadán, R., & Ott, A. (2021) · medRxiv · doi:10.1101/2021.06.10.21258550 · Cited by 3
Wilson, P. C., Changrob, S., Fu, Y., Guthmiller, J. J., Halfmann, P., Li, L., Stamper, C. T., Dugan, H. L., Accola, M. A., Rehrauer, W. M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-678247/v1 · Cited by 3
Verdurme, L., Danesh, G., Trombert‐Paolantoni, S., Sofonea, M. T., Noel, V., Foulongne, V., Montès, B., Tuaillon, É., Haïm‐Boukobza, S., Roquebert, B., et al. (2021) · medRxiv · doi:10.1101/2021.09.13.21263371 · Cited by 3
Nkosi, T., Chasara, C., Mbatha, A., Nsimbi, M., Papadopoulos, A. O., Nguni, T. L., Karim, F., Moosa, M. Y. S., Gazy, I., Jambo, K., et al. (2022) · medRxiv · doi:10.1101/2022.04.05.22273453 · Cited by 3
Schiepers, A., Wout, M. F. L. V. ’., Greaney, A. J., Zang, T. M., Muramatsu, H., Lin, P. J. C., Tam, Y. K., Mesin, L., Starr, T. N., Bieniasz, P. D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.29.505743 · Cited by 3
Self-citationCurtis, N. C., Shin, S., Hederman, A. P., Connor, R. I., Wieland‐Alter, W., Ionov, S., Boylston, J. A., Rose, J., Sakharkar, M., Dorman, D. B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.08.556349 · Cited by 4
Rational design of a covalent ACE2 decoy receptor that broadly neutralizes SARS ‐ CoV ‐2 variants
Hino, N., Takada, R., Suzuki, K., Tokunoh, N., Karaki, T., Ohtake, K., Ogami, H., Nishiura, T., Ishimoto, K., Tsukamoto, T., et al. (2025) · Protein Science · doi:10.1002/pro.70306 · Cited by 3
Enhanced Sampling Reveals Metastable Conformations Driving K417N-Mediated Class I Antibody Escape
Pan, X., Tadokoro, T., Onodera, T., Kita, S., Takahashi, Y., Maenaka, K., & Dokainish, H. M. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01396 · Cited by 2
Metadata
- Authors
- Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D.
- Affiliations
- Fred Hutch Cancer Center (US)
- University of Washington (US)
- Brigham and Women's Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Bloom, Jesse D.
- ORCID
- Venue
- Science
- Published
- 2021-02-19
- Volume
- 371
- Issue
- 6531
- Pages
- 850-854
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963219
- OpenAlex
- W3125266951
- Cited by
- 743
- References
- 40
- Citations by year
- 2026: 31 · 2025: 37 · 2024: 56 · 2023: 104 · 2022: 232 · 2021: 279
- FWCI
- 53.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- Funders
- Howard Hughes Medical Institute (Investigator)
- National Institute of Allergy and Infectious Diseases (R01AI127893, R01AI141707)
- Bill and Melinda Gates Foundation (INV-004949)
- Damon Runyon Cancer Research Foundation (DRG-2381-19)
- Massachusetts Consortium for Pathogen Readiness
- Washington Research Foundation (Innovation Fellow)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, COVID-19 pandemic, antibody escape, receptor binding domain, viral mutations, monoclonal antibodies, antibody binding, viral surveillance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.